Angela Hewlett

MedicineHealth Professions

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial”.

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(21)00384-2

N/A

4.4DataRank · unranked

167 citations

Aneesh K Mehta, Thomas F Patterson, Nathaniel Erdmann, Carlos A Gomez, Mamta K Jain +95 more

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00088-1

N/A

3.0DataRank · unranked

128 citations

Kay M Tomashek, Thomas F. Patterson, Carlos A. Gómez, Vincent C. Marconi, Mamta K. Jain +95 more

Ebola virus disease

Nature Reviews Disease Primers(2020)10.1038/s41572-020-0147-3

N/A

0.965DataRank · unranked

620 citations

Ian Crozier, William A. Fischer, Angela Hewlett, Colleen S. Kraft, Marc-Antoine de La Vega +6 more

SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae198

N/A

0.439DataRank · unranked

13 citations

Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert, Robin Dewar +94 more

Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial

The Lancet Microbe(2024)10.1016/s2666-5247(24)00163-0

N/A

0.393DataRank · unranked

8 citations

Gary Collins, Nadine Rouphael, Guillaume Poliquin, Rosemary McConnell, Gabrielle Grubbs +21 more